Tian-mei Zeng
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Journal: Clinical and translational medicine
Published: January 19, 2024
PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK.
Journal: Science translational medicine
Published: July 12, 2023
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.
Journal: Nature communications
Published: September 15, 2022
Current and emerging immunotherapeutic approaches for biliary tract cancers.
Journal: Hepatobiliary & pancreatic diseases international : HBPD INT
Published: June 23, 2022
Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
Journal: Frontiers in immunology
Published: May 13, 2022
PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma.
Journal: Science translational medicine
Published: May 13, 2019
The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed/refractory multiple myeloma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: May 15, 2013
Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: May 15, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026